Known tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib) initially identified as blockers of the tyrosine kinase BCR-ABL for potential use in cancer, display also the ability to block collagen-mediated DDR1 autophosphorylation. This evidence concerns the gene DDR1 and cancer.